Pulmonx Corporation (LUNG)
6.82
0.03 (0.44%)
At close: Mar 28, 2025, 3:59 PM
6.82
0.07%
After-hours: Mar 28, 2025, 04:20 PM EDT
0.44% (1D)
| Bid | 5.1 |
| Market Cap | 271.21M |
| Revenue (ttm) | 85.26M |
| Net Income (ttm) | -57.38M |
| EPS (ttm) | -1.44 |
| PE Ratio (ttm) | -4.73 |
| Forward PE | -3.83 |
| Analyst | Buy |
| Ask | 7.8 |
| Volume | 262,182 |
| Avg. Volume (20D) | 314,151 |
| Open | 6.76 |
| Previous Close | 6.79 |
| Day's Range | 6.47 - 7.02 |
| 52-Week Range | 5.46 - 10.01 |
| Beta | 0.51 |
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 1, 2020
Employees 291
Stock Exchange NASDAQ
Ticker Symbol LUNG
Website https://pulmonx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 76.08% from the latest price.
Stock ForecastsNext Earnings Release
Pulmonx Corporation is scheduled to release its earnings on Apr 30, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+32.23%
Pulmonx shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago
-5.01%
Pulmonx shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 sales guidance above estimates.
